Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.48 |
| ▸ | BDKRB2 | P30411 | 5/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30626180 | 1.00 | OPRM1 (0.51) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL30184771 | 0.96 | OPRM1 (0.47) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL29595585 | 0.96 | OPRM1 (0.47) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL31752434 | 0.95 | CAPN1 (0.48) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL29760883 | 0.93 | CAPN1 (0.55) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL30321101 | 0.92 | CAPN1 (0.46) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL30626178 | 0.91 | CAPN1 (0.43) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL30139003 | 0.91 | CAPN1 (0.43) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL30167004 | 0.90 | CAPN1 (0.46) | OPRM1OPRD1CAPN1BDKRB2CTSB | |
| SCHEMBL29375301 | 0.90 | CAPN1 (0.46) | OPRM1OPRD1CAPN1BDKRB2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285583-A1 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST | HANMI PHARM. CO., LTD. (KR) | 2023-09-14 | — | — | US | claimed |
| EP-4154870-A1 | LIQUID PREPARATION OF LONG-ACTING CONJUGATE OF GLUCAGON/GLP-1/GIP TRIGONAL AGONIST | Hanmi Pharm. Co., Ltd. (KR) | 2023-03-29 | — | — | EP | claimed |
| CN-115811970-A | Liquid formulations of long-acting conjugates of glucagon, GLP-1 and GIP triple agonists | 韩美药品株式会社 | 2023-03-17 | — | — | CN | claimed |
| WO-2025264785-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025016303-A1 | GLP-1, GIP AND GCG RECEPTOR TRIAGONIST AND USE THEREOF | 北京拓界生物医药科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230303640-A1 | EXENDIN-4 PEPTIDE ANALOGS | TXP PHARMA AG (CH) | 2023-09-28 | — | — | US | disclosed |
| US-20230285583-A1 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST | HANMI PHARM. CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-4196495-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP Pharma GmbH (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | SHENZHEN TURIER BIOTECH CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4154870-A1 | LIQUID PREPARATION OF LONG-ACTING CONJUGATE OF GLUCAGON/GLP-1/GIP TRIGONAL AGONIST | Hanmi Pharm. Co., Ltd. (KR) | 2023-03-29 | — | — | EP | disclosed |
| CN-115819551-A | GLP-1/glucagon/gastrin receptor triple agonist with site-specific modification and application thereof | 南京赛诺生物制药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115811970-A | Liquid formulations of long-acting conjugates of glucagon, GLP-1 and GIP triple agonists | 韩美药品株式会社 | 2023-03-17 | — | — | CN | disclosed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | IAPP, PNLIP, DPP4 | OPRM1 656/4885OPRD1 790/4885CAPN1 2127/4885 |
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | GLP1R, GCGR, GIPR | OPRM1 3338/4885OPRD1 2819/4885CAPN1 3687/4885 |
| US-20230285583-A1 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST | GLP1R, GIPR, GCG | OPRM1 1902/4885OPRD1 1691/4885CAPN1 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.